Lenalidomide, Adriamycin and Dexamethason (RAD) in Relapsed and Refractory Multiple Myeloma: Final Results from a Phase I/II Trial of "Deutsche Studiengruppe Multiples Myelom".

被引：0
|
作者：
Gerecke, Christian [1 ]
Knop, Stefan [2 ]
Topp, Max S. [2 ]
Liebisch, Peter [3 ]
Vollmuth, Christina [2 ]
Platzbecker, Uwe [4 ]
Maeder, Uwe [5 ]
Einsele, Hermann [6 ]
Bargou, Ralf C. [2 ]
机构：
[1] Helios Hosp Berlin Buch, Berlin, Germany
[2] Univ Wurzburg, Med Ctr, Wurzburg, Germany
[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[4] Univ Hosp Dresden, Dresden, Germany
[5] Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[6] Univ Wurzburg, Dept Hematol Oncol, Wurzburg, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：961 / 961
页数：1
相关论文
共 50 条
  • [31] The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma - First Results of a phase II Trial by the German DSMM Group
    Knop, Stefan
    Langer, Christian
    Engelhardt, Monika
    Muegge, Lars
    Reichle, Albrecht
    Roellig, Christoph
    Gramatzki, Martin
    Roesler, Wolf
    Topp, Max S.
    Wesemeier, Carmen
    Hertenstein, Bernd
    Sturm, Isrid
    Dechow, Tobias
    Kortuem, Martin
    Sauerwein, Marianne
    Einsele, Hermann
    Bargou, Ralf
    BLOOD, 2010, 116 (21) : 810 - 810
  • [32] Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective 'Deutsche Studiengruppe Multiples Myelom' (DSMM) Analysis
    Graziani, Giulia
    Herget, Georg W.
    Ihorst, Gabriele
    Schafer, Henning
    Neubauer, Jakob
    May, Annette M.
    Duyster, Justus
    Einsele, Hermann
    Wasch, Ralph
    Engelhardt, Monika
    BLOOD, 2017, 130
  • [33] Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial
    Richardson, Paul G.
    Wolf, Jeffrey Lee
    Jakubowiak, Andrzej J.
    Zonder, Jeffrey A.
    Lonial, Sagar
    Irwin, David
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur S.
    Bar, Michael H.
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Martin, Thomas
    Laubach, Jacob P.
    Allerton, Jeffrey P.
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    BLOOD, 2011, 118 (21) : 371 - 371
  • [34] PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
    Bilotti, El
    Vesole, D.
    Richter, J.
    McNeill, A.
    Anand, P.
    Bednarz, U.
    Ivanovski, K.
    McBride, L.
    Raucci, L.
    Batra, V.
    Siegel, D.
    HAEMATOLOGICA, 2013, 98 : 323 - 324
  • [35] RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
    Palumbo, A.
    Larocca, A.
    Sanpaolo, G.
    Falcone, A. P.
    Federico, V.
    Canepa, L.
    Crugnola, M.
    Baldini, L.
    Magarotto, V.
    Falco, P.
    Petrucci, M. T.
    Boccadoro, M.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S14 - S15
  • [36] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Dhakal, Binod
    D'Souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos
    Schroeder, Katrina
    Chhabra, Saurabh
    Shah, Nirav N.
    Gauger, Katelyn
    Keaton, Taylor
    Pasquini, Marcelo
    Hari, Parameswaran
    BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [37] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Binod Dhakal
    Anita D’Souza
    Mehdi Hamadani
    Carlos Arce-Lara
    Katrina Schroeder
    Saurabh Chhabra
    Nirav N. Shah
    Katelyn Gauger
    Taylor Keaton
    Marcelo Pasquini
    Parameswaran Hari
    Blood Cancer Journal, 9
  • [38] Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
    Palumbo, Antonio
    Larocca, Alessandra
    Genuardi, Mariella
    Kotwica, Katarzyna
    Gay, Francesca
    Rossi, Davide
    Benevolo, Giulia
    Magarotto, Valeria
    Cavallo, Federica
    Bringhen, Sara
    Rus, Cecilia
    Masini, Luciano
    Iacobelli, Massimo
    Gaidano, Gianluca
    Mitsiades, Constantine
    Anderson, Kenneth
    Boccadoro, Mario
    Richardson, Paul
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (07): : 1144 - 1149
  • [39] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Laubach, Jacob P.
    Shain, Kenneth H.
    Baz, Rachid
    Boswell, Erica N.
    Henrick, Patrick M.
    Azab, Abdel Kareem
    Hanlon, Courtney
    Chuma, Stacey
    Leblebjian, Houry
    Noonan, Kimberly
    MacNabb, Megan H.
    Warren, Diane
    Armand, Philippe
    Paba-Prada, Claudia E.
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [40] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Shain, Kenneth
    Hanlon, Courtney
    Banwait, Ranjit
    Azab, Abdel Kareem
    Laubach, Jacob P.
    Armand, Philippe
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Chuma, Stacey
    Boswell, Erica N.
    Mostyn, Patrick
    Houry, Leblebjian
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2013, 122 (21)
12345